While mortality rates were similar between percutaneous coronary intervention and coronary artery bypass grafting in both EXCEL and NOBLE trials, the risk of major cardiovascular events was higher in PCI in NOBLE.
At 1 year, primary patency was 82.3% for the drug-coated balloon group vs 70.9% for the percutaneous transluminal angioplasty group.
Procedural data from the WATCHMAN clinical trial presented at TCT demonstrated the device implantation success rate in patients with nonvalvular atrial fibrillation.
The Sentinel transcatheter cerebral embolic protection device was safe and captured 99% of debris in patients undergoing TAVR.
Transcatheter aortic valve replacement with SAPIEN valve demonstrates long-term durability and improves quality of life.
The 1-year target lesion failure was 8.3% for patients with diabetes which was significantly lower than the pre-specified goal of 12.7%.
First look at research to be presented at TCT 2016.
